GBI Research’s pharma report, "Pharmaceutical Research and Development (R&D) - Increasing Efficency Through Information Technology and Externalization" provides key data, information and analysis on major pharmaceutical R&D practices at the global level in order to improve its efficiency and effectiveness. This pharmaceutical and healthcare report provides comprehensive insight into the major challenges in the current pharmaceutical R&D landscape. It analyzes key measures and practices (mergers and acquisitions, R&D restructuring, outsourcing and active lifecycle management) adopted by the pharmaceutical industry to tackle these challenges and improve the R&D efficiency. The report substantiates the analysis with various case studies to study the effect of measure post-implementation. The report also provides an analytical insight into the potential solutions that have tremendous potential to improve the future pharmaceutical and biotech R&D productivity.

The pharmaceutical industry has witnessed a significant decline in R&D productivity over the past few years, which has become a matter of concern among the key stakeholders in the industry, particularly the pharmaceutical companies. While the R&D expenditure of the industry has steadily increased, the output has been declining. The increase in the number of late-stage development failures is costing the pharmaceutical industry dearly. In addition, the stringent regulatory mechanisms on the pricing and reimbursement of approved drugs have added to the pressure. Pharmaceutical companies have tried many ways to improve the R&D efficiency which include the acquisitions of small biotechnology and pharmaceutical companies, R&D restructuring, outsourcing and better lifecycle management of their existing drugs in the market. However, there has been limited success achieved to date.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts.

Scope

The report analyses the key measures adopted to improve the R&D efficiency in the pharmaceutical and biotech industry along with the major challenges that have led to a decrease in the R&D productivity over the last decade. The scope of the report includes:

• Major challenges in the current pharmaceutical R&D landscape.

• Key solutions adopted by the pharmaceutical industry to improve the R&D productivity which include strategic mergers and acquisitions, R&D restructuring, outsourcing and active lifecycle management.

• More than 25 examples and case studies explaining each solution and its impact on the R&D productivity in a short and long term.

• Qualitative analysis of the major potential solutions that can improve the R&D productivity in the future.

Reasons to buy

The report will enhance your decision making. It will allow you to:

• Identify the key R&D challenges in the industry and its impact on your company's R&D productivity.

• Understand the three different focus areas of improving R&D efficiency and select the one best suited to the company’s long term business strategy.

• Develop more efficient and effective solutions by identifying the implementation issues from the case studies and examples covered for each solution.

• Ensure sustainable R&D growth by identifying long term potential solutions to improve R&D efficiency.

• Create an integrated and agile R&D organization through the understanding of key technologies and other external partners in improving the R&D efficiency in future.

• Optimize R&D efforts by identifying the key areas with maximum revenue potential in future.